QNCX

Quince Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website quincetx.com
Employees(FY) 21
ISIN US22053A1079

Performance

+6.12%

+35.06%

+201.01%

+150.6%

+98.1%

YTD

+110.1%

Profile

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Advanced Technical Analysis

Technical Analysis of QNCX 2024-12-02

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 73 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of QNCX

Stock Rank

Recent News & Updates

2024-11-13 03:05
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results(Businesswire)
2024-11-12 03:05
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research(Businesswire)
2024-11-11 03:05
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting(Businesswire)
2024-10-14 04:05
Quince Therapeutics to Participate at Upcoming Investor Conferences(Businesswire)
2024-09-03 04:05
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference(Businesswire)
2024-08-15 16:12
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial(Yahoo Finance)
2024-08-14 19:00
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)(Businesswire)
2024-08-13 04:05
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results(Businesswire)
2024-06-25 19:13
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial(Yahoo Finance)
2024-06-24 19:00
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia(Businesswire)
2024-06-03 19:15
FDA fast tracks Quince Therapeutics rare ataxia drug EryDex(Yahoo Finance)
2024-06-02 19:00
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System(Businesswire)
2024-05-13 01:53
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-12 19:00
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results(Businesswire)
2024-05-06 04:05
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference(Businesswire)
2024-04-01 21:53
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023(Investorplace)
2024-03-31 19:00
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results(Businesswire)
2024-02-21 18:00
Quince Therapeutics Launches Scientific Advisory Board(Businesswire)
2024-02-14 18:00
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors(Businesswire)
2024-02-07 03:05
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference(Businesswire)
2024-01-04 03:05
Quince Therapeutics to Participate at Investor Events in January 2024(Businesswire)
2023-12-03 18:21
10 Best Debt Free Penny Stocks To Buy Now(Yahoo Finance)
2023-10-22 19:00
Quince Therapeutics Completes Acquisition of EryDel S.p.A.(Businesswire)
2023-09-28 04:05
U.S. FDA Partial Clinical Hold Lifted on IND for EryDels Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia(Businesswire)
2023-09-05 19:00
Quince Therapeutics Appoints Dr. Charles S. Ryan as President(Yahoo Finance)
2023-08-14 22:20
Sidoti Events, LLCs Virtual August Micro-Cap Conference(Yahoo Finance)
2023-08-10 04:05
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023(Yahoo Finance)
2023-07-23 19:00
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity(Yahoo Finance)
2023-07-12 20:00
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.(Yahoo Finance)
2023-06-05 20:00
Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.